Clinical Report: FDA Approves Baxdrostat for Resistant Hypertension
Overview
The FDA has approved baxdrostat as the first aldosterone synthase inhibitor for treating resistant hypertension. In the Phase 3 BaxHTN trial, baxdrostat demonstrated significant reductions in systolic blood pressure in patients with uncontrolled hypertension despite standard therapy.
Background
Resistant hypertension remains a significant clinical challenge, affecting approximately half of patients on multiple antihypertensive medications. Elevated aldosterone levels contribute to persistent hypertension and associated cardiovascular risks. The introduction of baxdrostat offers a new therapeutic option targeting aldosterone synthesis, potentially improving outcomes for these patients.
Data Highlights
Group
Reduction from Baseline (mmHg)
Placebo-Adjusted Reduction (mmHg)
Baxdrostat 2 mg
15.7
9.8
Baxdrostat 1 mg
14.5
8.7
Placebo
5.8
N/A
Key Findings
Baxdrostat is the first aldosterone synthase inhibitor approved for resistant hypertension.
The Phase 3 BaxHTN trial included 796 patients and showed significant reductions in systolic blood pressure.
At 12 weeks, patients on baxdrostat 2 mg had a 15.7 mmHg reduction from baseline.
Baxdrostat lowered aldosterone levels without affecting cortisol levels.
Approximately 50% of patients on multiple antihypertensive medications still experience uncontrolled hypertension.
Clinical Implications
Baxdrostat provides a novel treatment option for patients with resistant hypertension, potentially improving blood pressure control in those who have not responded to standard therapies. Clinicians should consider this medication for patients with persistent hypertension despite optimal treatment regimens.
Conclusion
The approval of baxdrostat represents a significant advancement in the management of resistant hypertension, addressing a critical need in this patient population. Ongoing research may further elucidate its role in broader cardiovascular and renal conditions.
Dr. Uprety discusses the current role of non-invasive testing for coronary artery disease, highlighting evidence-based diagnostic strategies and the appropriate use of imaging modalities to improve early detection, risk stratification, and clinical decision-making.
Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.
